PNC Financial Services Group’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$35.9K Buy
1,107
+660
+148% +$25.2K ﹤0.01% 3531
2026
Q2
$16.6K Sell
447
-16
-3% -$517 ﹤0.01% 3825
2026
Q1
$14.7K Sell
463
-45
-9% -$1.23K ﹤0.01% 3782
2025
Q4
$13.8K Sell
508
-13
-2% -$342 ﹤0.01% 3789
2025
Q3
$13.5K Buy
521
+257
+97% +$5.96K ﹤0.01% 3780
2025
Q2
$5.37K Buy
264
+165
+167% +$3.21K ﹤0.01% 4068
2025
Q1
$1.8K Buy
99
+92
+1,314% +$2.06K ﹤0.01% 4366
2024
Q4
$177 Sell
7
-238
-97% -$6.47K ﹤0.01% 4656
2024
Q3
$8.33K Sell
245
-186
-43% -$7.09K ﹤0.01% 3826
2024
Q2
$16K Buy
431
+39
+10% +$1.47K ﹤0.01% 3535
2024
Q1
$16.5K Sell
392
-33
-8% -$1.36K ﹤0.01% 3487
2023
Q4
$16.9K Buy
425
+33
+8% +$971 ﹤0.01% 3459
2023
Q3
$10.8K Sell
392
-240
-38% -$7.52K ﹤0.01% 3657
2023
Q2
$21.4K Buy
632
+148
+31% +$4.99K ﹤0.01% 3463
2023
Q1
$17.4K Hold
484
– – ﹤0.01% 3501
2022
Q4
$21.6K Buy
484
+397
+456% +$14.2K ﹤0.01% 3372
2022
Q3
$2K Sell
87
-13
-13% -$399 ﹤0.01% 4147
2022
Q2
$3K Buy
+100
New +$2.9K ﹤0.01% 4082
2021
Q1
– Sell
-1,000
Closed -$18K – 4114
2020
Q4
$18K Hold
1,000
– – ﹤0.01% 3338
2020
Q3
$15K Buy
+1,000
New +$11.7K ﹤0.01% 3297
2019
Q4
– Sell
-79
Closed – – 3998
2019
Q3
$0 Hold
79
– – ﹤0.01% 3998
2019
Q2
$0 Hold
79
– – ﹤0.01% 4023
2019
Q1
$0 Sell
79
-1
-1% – ﹤0.01% 4039
2018
Q4
$0 Hold
80
– – ﹤0.01% 4052
2018
Q3
$1K Hold
80
– – ﹤0.01% 3992
2018
Q2
$1K Hold
80
– – ﹤0.01% 4011
2018
Q1
$3K Hold
80
– – ﹤0.01% 3949
2017
Q4
$3K Sell
80
-67
-46% -$2.87K ﹤0.01% 3917
2017
Q3
$6K Hold
147
– – ﹤0.01% 3788
2017
Q2
$5K Hold
147
– – ﹤0.01% 3773
2017
Q1
$8K Sell
147
-53
-27% -$2.76K ﹤0.01% 3559
2016
Q4
$11K Sell
200
-967
-83% -$55K ﹤0.01% 3403
2016
Q3
$71K Sell
1,167
-36
-3% -$2.24K ﹤0.01% 2508
2016
Q2
$79K Sell
1,203
-28
-2% -$1.78K ﹤0.01% 2490
2016
Q1
$70K Buy
1,231
+333
+37% +$37.5K ﹤0.01% 2554
2015
Q4
$211K Buy
898
+75
+9% +$16.4K ﹤0.01% 1879
2015
Q3
$130K Sell
823
-52
-6% -$14.7K ﹤0.01% 2206
2015
Q2
$331K Buy
875
+18
+2% +$7.15K ﹤0.01% 1717
2015
Q1
$358K Buy
857
+7
+0.8% +$2.5K ﹤0.01% 1654
2014
Q4
$233K Buy
850
+17
+2% +$4.23K ﹤0.01% 1793
2014
Q3
$162K Hold
833
– – ﹤0.01% 1912
2014
Q2
$204K Buy
833
+66
+9% +$14.9K ﹤0.01% 1735
2014
Q1
$203K Hold
767
– – ﹤0.01% 1728
2013
Q4
$278K Hold
767
– – ﹤0.01% 1548
2013
Q3
$407K Buy
767
+534
+229% +$183K ﹤0.01% 1307
2013
Q2
$55K Hold
233
– – ﹤0.01% 2226

Other funds holding CLDX

PNC Financial Services Group's CLDX Position: Q3 2026 in Review

PNC Financial Services Group increased its Celldex Therapeutics (CLDX) stake by 148% in Q3 2026, buying an estimated $25.2K and bringing the position to 1,107 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3531.

PNC Financial Services Group first reported a position in CLDX in Q2 2013 and has held it in 46 quarters since. The position peaked at $407K in Q3 2013. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • PNC Financial Services Group held 1,107 shares of Celldex Therapeutics worth $35.9K as of Q3 2026.
  • PNC Financial Services Group bought 660 Celldex Therapeutics shares in Q3 2026, an estimated $25.2K.
  • Celldex Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3531 holding.
  • PNC Financial Services Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • PNC Financial Services Group's Celldex Therapeutics position peaked at $407K in Q3 2013.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.